🚀 VC round data is live in beta, check it out!
Chosa Oncology Valuation Multiples
Discover revenue and EBITDA valuation multiples for Chosa Oncology and similar public comparables like CalciMedica, Vivesto, Futura Medical, Pure Biologics and more.
Chosa Oncology Overview
About Chosa Oncology
Chosa Oncology AB is a biotechnology company engaged in the research and development in immunotherapy on therapeutic cancer vaccines.
Founded
2007
HQ
Employees
4
Website
Sectors
Financials (FY)
EV
$9M
Chosa Oncology Financials
Chosa Oncology reported last fiscal year revenue of — and negative EBITDA of ($565K).
In the same fiscal year, Chosa Oncology generated $503K in gross profit, ($565K) in EBITDA losses, and had net loss of ($613K).
Chosa Oncology P&L
In the most recent fiscal year, Chosa Oncology reported revenue of — and EBITDA of ($565K).
Chosa Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Gross Profit | — | XXX | $503K | XXX | XXX | XXX |
| EBITDA | — | XXX | ($565K) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($613K) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Chosa Oncology Stock Performance
Chosa Oncology has current market cap of $10M, and enterprise value of $9M.
Market Cap Evolution
Chosa Oncology's stock price is $0.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9M | $10M | 0.3% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialChosa Oncology Valuation Multiples
Chosa Oncology trades at (15.3x) EV/EBITDA.
Chosa Oncology Financial Valuation Multiples
As of April 19, 2026, Chosa Oncology has market cap of $10M and EV of $9M.
Equity research analysts estimate Chosa Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Chosa Oncology has a P/E ratio of (15.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10M | XXX | $10M | XXX | XXX | XXX |
| EV (current) | $9M | XXX | $9M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (15.3x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (12.7x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 17.2x | XXX | XXX | XXX |
| P/E | — | XXX | (15.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (9.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Chosa Oncology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Chosa Oncology Margins & Growth Rates
Chosa Oncology's revenue in the last fiscal year grew by —.
Chosa Oncology's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.
Chosa Oncology Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (42%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Chosa Oncology Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Chosa Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| CalciMedica | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivesto | XXX | XXX | XXX | XXX | XXX | XXX |
| Futura Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Pure Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Liminatus Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Chosa Oncology M&A Activity
Chosa Oncology acquired XXX companies to date.
Last acquisition by Chosa Oncology was on XXXXXXXX, XXXXX. Chosa Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Chosa Oncology
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialChosa Oncology Investment Activity
Chosa Oncology invested in XXX companies to date.
Chosa Oncology made its latest investment on XXXXXXXX, XXXXX. Chosa Oncology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Chosa Oncology
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Chosa Oncology
| When was Chosa Oncology founded? | Chosa Oncology was founded in 2007. |
| Where is Chosa Oncology headquartered? | Chosa Oncology is headquartered in Sweden. |
| How many employees does Chosa Oncology have? | As of today, Chosa Oncology has over 4 employees. |
| Is Chosa Oncology publicly listed? | Yes, Chosa Oncology is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Chosa Oncology? | Chosa Oncology trades under CHOSA ticker. |
| When did Chosa Oncology go public? | Chosa Oncology went public in 2016. |
| Who are competitors of Chosa Oncology? | Chosa Oncology main competitors are CalciMedica, Vivesto, Futura Medical, Pure Biologics. |
| What is the current market cap of Chosa Oncology? | Chosa Oncology's current market cap is $10M. |
| Is Chosa Oncology profitable? | No, Chosa Oncology is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.